Back

Cardioprotective efficacy of combined therapy with azilsartan, indapamide, and nitrendipine in patients with essential hypertension

30 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Hypertension target organ damage Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Zaringiz Mashkurova

Republican Specialized Scientific Practical Medical Center Of Cardiology, Tashkent (Uzbekistan)

8 More presentations in this session

Presentation thumbnail
Orthostatic blood pressure changes and incident atrial fibrillation in patients with hypertension: Insights from the SPRINT trial
Doctor J. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Diagnostic and prognostic value of ECG-predicted hypertension mediated left ventricular hypertrophy using machine learning
Doctor H. Naderi (London, GB)
Abstract Slides Video
Presentation thumbnail
Carotid-Femoral pulse wave velocity progression in hypertensive patients is associated with subsequent cardiovascular outcomes
Doctor A. Maloberti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance (CMR) height-based allometric scaling in Southeast Asians; implications in the diagnosis and prognosis of left ventricular hypertrophy (LVH): the REMODEL study
Mr C. Lee (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Relationship between renin, aldosterone, aldosterone-to-renin ratio and left ventricular mass index in young adults
Doctor R. Ananda (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension target organ damage

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
The effect of fixed combination of medications (lisinopril 5mg + amlodipine 5mg + rosuvastatin 10mg) on some parameters of 24-hour blood pressure monitoring in patients with arterial hypertension
thumbnail
Congress Presentation
Efficacy and safety of low-dose antihypertensive combination drugs including amlodipine, telmisartan, and chlorthalidone: a multicenter, randomized, double-blinded, parallel, phase III clinical trial
thumbnail
Congress Presentation
Efficacy and safety of single-pill combination perindopril/amlodipine switched from combinations of other renin-angiotensin system inhibitors and calcium channel blockers: results from ESPRIT trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources